Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World September 26, 2012 Andrew Turley	Sanofi to cut 900 jobs in France It is not planning to move or close any of its industrial sites in France, but the future of the R&D site in Toulouse, which employs over 600 people, remains uncertain.
BusinessWeek February 21, 2005 Raphael Kahane	French Dailies: Help Wanted To counter freebies, old-line papers are linking up with Big Business.
BusinessWeek October 6, 2003 John Rossant	The Real War Is France vs. France Resentment of the U.S. is being challenged by a growing cadre of French thinkers.
BusinessWeek February 9, 2004 Kerry Cappell	This Bid Looks Like Bad Medicine Sanofi's lowball offer for giant drugmaker Aventis is unwise for both companies
Chemistry World October 14, 2010 Laura Howes	France and Spain commit funds to research The 'knowledge economy' has been declared a priority for the governments of both France and Spain, as they announce extra funds for higher education and research in their 2011 budgets.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
Chemistry World December 10, 2012 Andrew Turley	EU companies increasing R&D Companies in the EU are increasing their investment in R&D, despite the difficult economic conditions, according to a report from the European Commission that looked at the global top 1500 R&D investors.
Pharmaceutical Executive July 1, 2009	French Revolution Chris Viehbacher's first fast and furious six months at the top of Sanofi-Aventis have heads spinning... and rolling.
InternetNews January 25, 2008	Newspaper Web Sites Draw Record Viewers Online growth offsets struggles in print for newspapers.
The Motley Fool March 7, 2011 Brian Orelli	Kids, Vaccines, and Deaths a Bad Combination Pfizer and Sanofi may not to be to blame, but when investing in drugmakers, you always have to be worried about drug safety. Fortunately this doesn't look like one of those issues.
IndustryWeek December 1, 2007 Jill Jusko	Hey Big Spender: By the Numbers A look at R & D spending in 2006.
The Motley Fool October 1, 2009 Rich Smith	Cheese-eating Surrender Monkeys ... Packing Heat? France's Dassault Aviation is working hard to capture a $7 billion contract to equip the Brazilian air force with three dozen Rafale fighter jets.
The Motley Fool April 26, 2004 J. Graham	Sanofi Finally Nabs Aventis The French drug companies make a deal to merge.
The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
The Motley Fool September 11, 2008 Brian Lawler	Will a Change Cure Sanofi? The drugmaker charts a different course for its future.
The Motley Fool October 4, 2010 Brian Orelli	That's No Way to Make Friends Sanofi goes hostile on Genzyme.
The Motley Fool November 20, 2008 Brian Orelli	Sanofi Breathing Easier Drugmaker Sanofi-Aventis settles a few patent disputes with generic-drugmaker nemeses.
BusinessWeek December 9, 2009 Kelley & Torsoli	Major Surgery at Sanofi CEO Chris Viehbacher has been on a buying spree and a charm offensive, both of which are reversing the drugmaker's losing streak.
IndustryWeek January 1, 2009 Jill Jusko	R&D Spending: By the Numbers While the software industry spends 13.6% on R&D as a percentage of sales, the chemicals and energy sector spends only 1%.
The Motley Fool October 17, 2007 Tom Taulli	Rodman & Renshaw Clones a Bear The biotech boutique has a shaky public offering.
The Motley Fool June 15, 2007 Brian Orelli	Get Your Uncle to Pay for Your Capital Improvements MedImmune and Sanofi-Aventis recently announced that they had convinced the U.S. government to pick up a majority of the tabs to renovate their plants. There aren't too many industries where you can invest in companies that get free money from the government.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.
Chemistry World December 21, 2015 Jennifer Newton	Mexico approves world's first dengue vaccine Dengvaxia from Sanofi's vaccines division, Sanofi Pasteur, protects against all four dengue virus serotypes and will be aimed at residents in endemic areas aged nine to 45.
Inc. June 2007 Leigh Buchanan	The 2007 Inner City 100 Profiles: 61-70 Brief profiles of companies ranked 61 to 70 in The 2007 Inner City 100.
InternetNews November 14, 2006 Roy Mark	Congress Urged to Extend R&R Tax Credit A wide range of technology trade groups called upon Congress today to stop playing politics with the extension of the research and development tax credit.
The Motley Fool July 19, 2007 Brian Orelli	Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts.
Chemistry World January 3, 2014 Ben Valsler	Sanofi suffers multiple sclerosis setback French pharmaceutical Sanofi has run into trouble after the US Food and Drug Administration rejected its multiple sclerosis drug Lemtrada (alemtuzumab).
The Motley Fool July 29, 2009 Brian Orelli	The Swine Flu Can't Save Sanofi No shocker there.
The Motley Fool January 26, 2005 Stephen D. Simpson	Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation.
The Motley Fool May 7, 2007 Brian Lawler	Sanofi Rolls the Lawsuit Dice Investors, don't be fooled by rosy results; litigation risk still looms for the French drugmaker.
IndustryWeek June 23, 2010	By The Numbers -- The Expense of R&D Among U.S.-owned businesses and U.S. affiliates of foreign companies, much of the R&D remained in the United States.
The Motley Fool March 15, 2004 Ben McClure	More R&D, Please Big tech players up the research and development ante.
The Motley Fool January 8, 2012	Born in the USA, Made in France: How McDonald's Succeeds in the Land of Michelin Stars To make it in France, McDonald's made itself look like a French company and offered French favorites.
The Motley Fool April 19, 2004 Ben McClure	Ruminations on R&D Spending on research and development is important. But can it help identify promising investments? It's pretty easy to spot companies that spend a lot of money on R&D. It's another thing to pick companies that translate R&D spending into higher stock prices.
The Motley Fool February 20, 2007 Brian Lawler	Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead.
The Motley Fool November 1, 2006 Brian Lawler	Le Generic Excuse for Sanofi Even with its massive pipeline, there may be problems ahead for Sanofi. Its two top drugs are exposed to generic threats as Sanofi fights in court to keep generic competitiors out of those markets. Investors, take note.
The Motley Fool January 10, 2012 Subhadeep Ghose	France Telecom Aims to Lighten Itself France Telecom sells Swiss subsidiary to British group.
Investment Advisor January 1, 2011 Savita Iyer-Ahrestani	Revolution and Reform France's trouble with retirement reform has done little to sway investors away from the country.
HBS Working Knowledge February 28, 2005 Cynthia Churchwell	Funding R&D for Neglected Diseases Research on vaccines for diseases that primarily affect low-income countries remains minimal---the risks are too high for developers. The book Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases suggests a solution.
Chemistry World September 17, 2012 Rebecca Trager	Dow tax case raises R&D questions US chemical firm Dow has lost a legal battle over claims for R&D tax credits -- on 7 September, a US appeals court ruled that the money the company was trying to recoup constituted indirect research costs.
The Motley Fool November 12, 2009 Kris Eddy	Drug Companies Should Think Smaller Sanofi-aventis looks to break R&D into smaller chunks; their collaboration with Regeneron Pharmaceuticals is a good example of the new strategy.
Geotimes May 2004 Megan Sever	French Science Crisis On March 9, more than 2,000 French science research laboratory directors and team leaders tendered their resignations of administrative and management duties in protest over what they call "draconian cuts" in government scientific spending and research jobs.
IEEE Spectrum December 2007 Hira & Ross	The R&D 100 A company's research budget tells you very little about its prospects.
BusinessWeek September 20, 2004 John Rossant	France: Fraying Ties To The Arab World Its pro-Arab diplomacy isn't helping in the wake of a kidnapping in Iraq.